IP Library Granted Patent US 11,117,919
Granted Patent B2
US 11,117,919 · App. 16/444,367 · Granted Sep 14, 2021

Icariside compound, preparation method thereof, and application thereof

Inventors: Lianquan Gu (Guangdong, CN); Changyou Wu (Guangdong, CN); Jinlin Zhou (Guangdong, CN); Yujing Lu (Guangdong, CN); Tianmiao Ou (Guangdong, CN); Baohua Huang (Guangdong, CN); Liwei Lin (Guangdong, CN)
Assignee: GOLDEN HEALTH (GUANGDONG) BIOTECHNOLOGY CO. LTD.
C07H17/07A61K8/602A61K9/0014A61P31/06A61P31/12A61P35/00A61P37/04A61Q19/00C07H1/00C07H1/08C12P19/60G01N33/5055
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,117,919
App. No.
16/444,367
Granted
Sep 14, 2021
Kind
B2
Abstract

An icariside compound as shown in Formula I wherein the compound is a natural chemical component in the traditional Chinese herbal epimedium or a chemically modified or a totally synthetic product based on the natural component. The compound can be used for preparing pharmaceuticals, health care products, cosmetic and skin care products and the like for improvement of immunity in a human body.

Claims (13)

1. A method for treating ascites cancer or tuberculosis comprising administering to a subject in need thereof a therapeutically effective amount of icariside compounds having the following formula:

wherein:

R 1 is OH, R 2 is OH, and R 3 is OCH3:

wherein the icariside compounds improve subject immunity by promoting subject cells to produce γ-interference.

2. A method for treating ascites cancer or tuberculosis comprising administering to a subject in need thereof a therapeutically effective amount of icariside compounds having the following formula:

wherein:

R 1 is OH, R 2 is OH, R 3 is OH;

wherein the icariside compounds improve subject immunity by promoting subject cells to produce γ-interference.

3. A method for treating ascites cancer or tuberculosis comprising administering to a subject in need thereof a therapeutically effective amount of icariside compounds having the following formula:

wherein:

R 1 is OCH 3 , R 2 is OH, R 3 is OCH 3 ; or;

R 1 is OH, R 2 is OCH 3 , R 3 is OCH 3 ;

wherein the icariside compounds improve subject immunity by promoting subject cells to produce γ-interference.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE IS "GOLDEN HEALTH (GUANGDONG) BIOTECHNOLOGY CO., LTD".THERE IS A COMMA AFTER "CO" PREVIOUSLY RECORDED ON REEL 057178 FRAME 0568. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNEE LISTED AS "GOLDEN HEALTH (GUANGDONG) BIOTECHNOLOGY CO. LTD". Recorded Aug 23, 2021
From: FOSHAN GOLDEN HEALTH TECHNOLOGY CO., LTD.
To: GOLDEN HEALTH (GUANGDONG) BIOTECHNOLOGY CO., LTD.
Reel/Frame 057255/0169 →
CHANGE OF NAME Recorded Aug 12, 2021
From: FOSHAN GOLDEN HEALTH TECHNOLOGY CO., LTD.
To: GOLDEN HEALTH (GUANGDONG) BIOTECHNOLOGY CO. LTD.
Reel/Frame 057178/0568 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 19, 2019
From: GU, LIANQUAN; WU, CHANGYOU; ZHOU, JINLIN; LU, YUJING; OU, TIANMIAO; HUANG, BAOHUA; LIN, LIWEI
To: FOSHAN GOLDEN HEALTH TECHNOLOGY CO., LTD.
Reel/Frame 049517/0628 →
Priority Claims (1)
CN 201510264195.5 · May 20, 2015 · national
Continuity (2)
Division 15745784
Related Publication 20190300560A1 · Oct 3, 2019